This article originally appeared on The Gateway Pundit and was republished with permission.
Guest post by Anthony Scott
Pharmaceutical giant Pfizer has reported a young boy died due to cardiac arrest after receiving the company’s experimental gene therapy for Duchenne muscular dystrophy.
A Pfizer spokesperson told Reuters in an exclusive email, “A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study.”
Pfizer’s gene therapy trial is currently testing children two to three-year-olds who have Duchenne muscular dystrophy.
According to Johns Hopkins Medicine, Duchenne muscular dystrophy (DMD) “is caused by a genetic problem in producing dystrophin, a protein that protects muscle fibers from breaking down when exposed to enzymes.”
Per Reuters:
A young patient died due to cardiac arrest after receiving Pfizer’s gene therapy being tested in a mid-stage trial for a muscle-wasting disorder called Duchenne muscular dystrophy(DMD), the drugmaker told Reuters on Tuesday.
“A fatal serious adverse event was reported as cardiac arrest for a participant in the Phase 2 DAYLIGHT study,” a company spokesperson told Reuters in an emailed response.
The trial is testing boys 2 to three years of age with DMD, a genetic muscle wasting disorder in which most patients lack the protein dystrophin which keeps muscles intact. The disorder affects an estimated one-in-3,500 male births worldwide.
“The patient received the investigational gene therapy, fordadistrogene movaparvovec, in early 2023,” as per a statement from a community letter attributed to the drugmaker’s DMD gene therapy team and posted by a nonprofit advocacy group.
READ:
Pfizer announced they are currently reviewing the patient’s data to understand what caused the boy to suffer an adverse event.
Copyright 2024 The Gateway Pundit
Click this link for the original source of this article.
Author: The Gateway Pundit
This content is courtesy of, and owned and copyrighted by, https://vigilantnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.